AMD 3465 hexahydrobromide

• CAT Number: I002397
• CAS Number: 185991-07-5
• Molecular Formula: C24H38N6 • 6HBr
• Molecular Weight: 896.10
• Purity: ≥95%
• Synonyms: N-(4-((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)benzyl)-1-(pyridin-2-yl)methanamine
• Target: Immunology/Inflammation
• Solubility: H2O: ≥ 38 mg/mL
• Storage: Store at -20°C
• IUPAC Name: N-(pyridin-2-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine;hexahydrobromide
• InChI: InChI=1S/C24H38N6.6BrH/c1-2-13-29-24(5-1)20-28-19-22-6-8-23(9-7-22)21-30-17-4-12-26-15-14-25-10-3-11-27-16-18-30;;;;;;/h1-2,5-9,13,25-28H,3-4,10-12,14-21H2;6*1H
• InChIKey: ARHBIBDGWDRBJH-UHFFFAOYSA-N
• SMILES: C1CNCCNCCCN(CCNC1)CC2=CC=C(C=C2)CNCC3=CC=CC=N3.Br.Br.Br.Br.Br.Br

AMD 3465 hexahydrobromide（Cat No.:I002397）is a potent and selective antagonist of the chemokine receptor CXCR4, which plays a crucial role in various physiological processes, including immune response and cancer metastasis. By blocking CXCR4, AMD 3465 interferes with the migration and proliferation of cancer cells, making it a potential therapeutic candidate for treating hematological malignancies and solid tumors. Additionally, its ability to modulate immune responses positions it as a valuable agent in addressing conditions like HIV and autoimmune diseases. Ongoing research is exploring its efficacy and safety in clinical settings, highlighting its promise in oncology and immunotherapy.

Reference

[1]. Rosenkilde MM, et al. Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor. J Biol Chem. 2007 Sep 14;282(37):27354-65.
[2]. Bodart V, et al. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4. Biochem Pharmacol. 2009 Oct 15;78(8):993-1000.